Early phase I study of a 99m Tc labeled anti-PD-L1 sdAb inSPECT/CT assessment of programmed death ligand-1expression in non-small cell lung cancer

Conclusions: This first in human study demonstrates that 99mTc-labeled anti-PD-L1-sdAb SPECT/CT imaging is safe and associated with acceptable dosimetry. Tumor uptake is readily visible against background tissues, particularly at 2h when the T:BP ratio correlates with IHC PD-L1 expression.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Xing, Y., Chand, G., Liu, C., Zhao, L., Ting, H. H., Zhao, J. Tags: Lung Cancer I: Molecular Biomarkers and Molecular Imaging Signatures Source Type: research